Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational H9N2 vaccine GSK2654911A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo |
| Group B | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo |
| Group C | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo |
| Group D | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo |
| Group E | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654909A and placebo |
| Group F | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 5 |
| Group G | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 6 |
| Group H | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 7 |
| Group I | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654911A formulation 8 |
| Group J | EXPERIMENTAL | Subjects will receive the investigational vaccine GSK2654909A |
| Placebo Group | PLACEBO_COMPARATOR | Subjects will receive Placebo |
| Name | Type | Description |
|---|---|---|
| Investigational H9N2 vaccine GSK2654911A | BIOLOGICAL | 2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm. |
| Investigational H9N2 vaccine GSK2654909A | BIOLOGICAL | 2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm. |
| Placebo | BIOLOGICAL | 1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm. |
Inclusion Criteria: * Male or female adults from 18 to 64 years of age (inclusive) at time of first study vaccination. * Written informed consent obtained from the subject. * Subjects who the investigator believes can and will comply with the requirements of the protocol. * Healthy subjects as esta...
GSK2654911A is an investigational H9N2 influenza vaccine being developed for the prevention of influenza. It is intended for use in adults 18 to 64 years of age. The vaccine is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GSK2654911A is being developed by GSK plc, a biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The company conducted a Phase 1 clinical trial to evaluate the vaccine's safety and immunogenicity in adult participants.
GSK2654911A is in Phase 1 clinical development. A single Phase 1 trial has been completed, with no active trials currently ongoing. The vaccine remains investigational and has not received regulatory approval for use in any country.
GSK2654911A has been studied in one completed Phase 1 clinical trial, identified as NCT01659086. This randomized, double-blind, placebo-controlled study evaluated the safety and immunogenicity of GSK2654911A and GSK2654909A in 422 healthy adults aged 18 to 64 years in the United States and Canada.
GSK2654911A and GSK2654909A are two separate investigational influenza vaccines developed by GSK plc. They were both evaluated in the same Phase 1 clinical trial, NCT01659086, which assessed the safety and immunogenicity of each vaccine in adults aged 18 to 64 years.